loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Bezuclastinib

    Client Email Product
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Menu

    Bezuclastinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cogent Reports Additional Bezuclastinib Data In NonAdvSM
    Cogent Reports Additional Bezuclastinib Data In NonAdvSM

    14 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/14/2898928/0/en/Cogent-Biosciences-Announces-Additional-Clinical-Data-from-Part-1-of-its-Ongoing-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM.html

    GLOBENEWSWIRE
    14 Jun 2024
    Share Share
    Cogent Bezuclastinib Peak Lead-In: Gist Phase 3 Positive At Asco
    Cogent Bezuclastinib Peak Lead-In: Gist Phase 3 Positive At Asco

    23 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/23/2887694/0/en/Cogent-Biosciences-Announces-Positive-Updated-Lead-In-Data-from-Ongoing-Phase-3-PEAK-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-in-Patients-with-Gastrointestinal-.html

    GLOBENEWSWIRE
    23 May 2024
    Share Share
    Cogent Announces Positive Part 1b Data from Trial Evaluating Bezuclastinib
    Cogent Announces Positive Part 1b Data from Trial Evaluating Bezuclastinib

    22 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/22/2834028/0/en/Cogent-Biosciences-Announces-Positive-Part-1b-Data-from-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-Nonadvanced-Systemic-Mastocytosis.html

    GLOBENEWSWIRE
    22 Feb 2024
    Share Share
    Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvSM
    Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvSM

    05 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/05/2823572/0/en/Cogent-Biosciences-to-Present-SUMMIT-Part-1b-Data-with-Bezuclastinib-in-NonAdvanced-Systemic-Mastocytosis-NonAdvSM-at-the-2024-AAAAI-Annual-Meeting.html

    GLOBENEWSWIRE
    05 Feb 2024
    Share Share
    Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib
    Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib

    09 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/09/2806211/0/en/Cogent-Biosciences-Announces-Planned-2024-Milestones-for-Bezuclastinib-and-Emerging-Portfolio-of-Selective-and-Potent-Targeted-Therapeutics.html

    GLOBENEWSWIRE
    09 Jan 2024
    Share Share
    Cogent Announces Positive Data from Phase 2 APEX Trial Evaluating Bezuclastinib
    Cogent Announces Positive Data from Phase 2 APEX Trial Evaluating Bezuclastinib

    11 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/11/2793781/0/en/Cogent-Biosciences-Announces-Positive-Data-from-Ongoing-Phase-2-APEX-Trial-Evaluating-Bezuclastinib-in-Patients-with-Advanced-Systemic-Mastocytosis-AdvSM.html

    GLOBENEWSWIRE
    11 Dec 2023
    Share Share